superficial vein thrombosis

quick recognition

• Erythema, warmth, tenderness along a palpable cord
• Greater saphenous vein involved in ~73%; small saphenous vein ~26%
• Varicose veins present in ~45–80% of cases
• More common in females (78–167 vs 49–116 per 100 000 person-years)
• Non-varicose SVT is a distinct higher-risk phenotype — higher recurrence and VTE progression than varicose-associated SVT → lower threshold for investigation

when to suspect concomitant DVT

• ~25% of SVT patients have DVT or PE at diagnosis (POST)
• In isolated SVT, 10.2% develop VTE at 3 months — even with ~60% receiving anticoagulation (POST). A larger community cohort (CPRD Aurum, n=293 166) found 3.5% DVT/PE within 90 days, with 51% of events in the first week and 77% within 30 days — the difference reflects POST’s selection of ultrasound-confirmed, ≥5 cm thrombi. Both support front-loading follow-up.
• 3-month mortality: 9.3% with concomitant DVT vs 1.2% without (OPTIMEV) → screening matters
• New dyspnoea or chest pain → CTPA

Risk factors for progression: male sex, history of VTE, absence of varicose veins, SFJ/SPJ involvement, active cancer

diagnosis

Clinical findings (tender palpable cord, erythema) are often sufficient, but compression ultrasound (CUS) is recommended to:

1. Confirm SVT and measure thrombus length
2. Assess proximity to SFJ or SPJ (where saphenous veins join the deep system)
3. Rule out concomitant DVT

Request SFJ/SPJ distance and thrombus length from radiology when not reported. CHEST 2021 specifically recommends ultrasonography for above-knee SVT.

management

concomitant DVT or PE

Therapeutic anticoagulation per Deep Vein Thrombosis protocol.

within 3 cm of the SFJ or SPJ

• Treat as proximal DVT → therapeutic anticoagulation × 3 months
• Evidence is extrapolated — RCTs excluded these patients — but risk of deep extension is high

SVT ≥5 cm, >3 cm from SFJ/SPJ

Prophylactic-dose anticoagulation × 45 days:

CHEST 2021 factors favouring anticoagulation: extensive SVT, above-knee location (especially near SFJ), severe symptoms, GSV involvement, prior VTE/SVT, active cancer, recent surgery.

SVT <5 cm, >3 cm from SFJ/SPJ

• Low risk: topical/oral NSAIDs, warm or cool compresses, elevation
• Higher risk (prior VTE/SVT, cancer, pregnancy, hormonal therapy, recent surgery) → consider prophylactic anticoagulation × 45 days
• If not anticoagulating → repeat CUS within 7–10 days if symptoms worsen or persist (proximal extension, diffuse oedema) — the goal is to rule out extension into deep veins, not to confirm thrombus resolution

IV cannula–associated SVT

Supportive care (warm compresses, topical NSAIDs) is usually sufficient. However, if there is symptomatic or sonographic progression, prophylactic anticoagulation is indicated; therapeutic dosing if thrombus extends close to the deep system. For PICC-associated SVT, catheter removal may not be necessary if anticoagulated or symptoms resolve.

upper extremity SVT

• Primarily catheter-related (peripheral IV, PICC, central lines)
• No high-quality RCTs of anticoagulation; data on subsequent PE risk are lacking
• Remove catheter if feasible; supportive care ± short-course anticoagulation if extensive
• If symptomatic or sonographic progression → prophylactic anticoagulation; therapeutic dosing if close to the deep system

other named entities

• Mondor disease — SVT of the thoracoabdominal wall, breast, or penile veins. Usually self-limited (4–8 weeks). In breast SVT, exclude underlying malignancy with imaging.
• Suppurative thrombophlebitis — infected thrombus, typically catheter-related. IV antibiotics ± surgical drainage. Signs: purulent drainage, high fever, bacteraemia despite catheter removal.

duration beyond 45 days

• No high-quality RCT evidence for treatment beyond 45 days
• One observational study: tinzaparin 131 IU/kg × 90 days (n=49) vs variable-dose × 30 days (n=98) → 0 vs 15 recurrences at 120 days (P=.004). Small, non-randomised, non-uniform dosing — interpret cautiously.
• Cochrane noted events rose after 45-day cessation in SURPRISE (unlike CALISTO) — may favour longer courses in higher-risk patients
• Extension beyond 45 days → individualise based on severity, persistent symptoms, and ongoing risk factors

surgery

• Do not refer for acute surgery — saphenofemoral disconnection vs enoxaparin (n=60) showed recurrent SVT/VTE of 10% in both arms, with wound complications in 6.7% of the surgical group. A prospective study (n=195) similarly showed no difference between urgent surgery and anticoagulation.
• Post-acute duplex to document reflux — reflux is the discriminator for who may benefit from deferred ablation
• Deferred ablation after medical treatment may be considered to prevent recurrence where reflux is documented, but no trial has tested varicose vein intervention against conservative management for the endpoint of SVT recurrence
• Historical SVT recurrence ~10–20%; ~6% in the anticoagulation era

recurrent SVT

workup

management of recurrence

• Repeat CUS → rule out deep extension
• Short-term anticoagulation (45 days) per initial algorithm
• Treat the underlying cause:
  • Varicose veins → post-acute duplex, then treat varicose disease if reflux (vascular referral)
  • Malignancy → cancer-directed therapy
  • APS → long-term Warfarin
  • Hormonal → stop oestrogen

special populations

malignancy

• ~6–17% of SVT patients have active cancer
• Cancer-associated SVT: RR 2.57 for subsequent VTE; 3-month mortality 8.2% vs 0.3% without cancer
• NCCN 2026 algorithm:
  • SVT >5 cm or above the knee → prophylactic-dose anticoagulation × ≥6 weeks
  • Within 3 cm of SFJ → therapeutic anticoagulation × ≥3 months
  • If not anticoagulating → repeat US in 7–10 days
• Migratory thrombophlebitis → reassess disease control

pregnancy

• No RCTs; guidelines actively disagree:
  • ASH 2018 — conditional, low-certainty suggestion for LMWH with no duration guidance
  • SOGC — prophylactic- or intermediate-dose LMWH for 1 to 6 weeks if bilateral, very symptomatic, ≤5 cm from a deep junction, or ≥5 cm of vein involved
• Untreated antepartum SVT → ~10% risk of subsequent VTE in same pregnancy (Danish cohort)
• If not anticoagulating → repeat CUS within 7–10 days
• Risk highest postpartum (1.6 vs 0.3 per 1000 person-years antepartum)
• Warfarin and DOACs contraindicated in pregnancy

what NOT to do

• Do not dismiss SVT as benign — 25% have concomitant DVT; 3.5–10% develop VTE at 3 months
• Do not skip ultrasound — clinical diagnosis alone misses junctional proximity and concomitant DVT
• Do not use D-dimer to exclude SVT — sensitivity only ~48–74%
• Do not use repeat ultrasound to confirm thrombus resolution — may persist for weeks; goal is to rule out extension
• Do not prescribe antibiotics unless there are signs of infection (suppurative thrombophlebitis)
• Do not routinely anticoagulate IV cannula–associated SVT (but do anticoagulate if progressing or near the deep system)
• Do not refer for acute surgery — no benefit over anticoagulation, added wound morbidity

key trials summary